| Input Symbol (pharmaceutics and related company): |
Show Other Options
| US Clinical Trail Options | |||
| Field(s): | Type(s): | Status(es): | Phase(s): |
| Default Sorting: | |||
| US FDA Submission Options | |||
| Field(s): | Class(s): | Type(s): | |
| US Drug Marketing Status Options | |||
| Field(s): | |||
| EU Drug Marketing Status Options | |||
| Field(s): | |||
| CA Drug Marketing Status Options | |||
| Field(s): | |||
| General Options | |||
| Historical Years: | Display Records Number: | ||
| Plot Options & Overlay | |||
| Price Chart: | Technical Indicators: | Clinical Trails: | FDA Submissions: |
| US Marketing: | EU Marketing: | CA Marketing: |
| Full Name:Takeda Pharmaceutical Company Limited | Industry:pharmaceuticals | CIK:1395064 | Fiscal Year End: | State/Country:JAPAN |
Check Quant Chart for other overlays (E.g. SEC filings, Insider tradings) to get more accurate projection of price movement
Show Plot Instructions Expand All
Instructions
US clinical trial status
Size of symbol reflects the phase of clinical trial. E.g. Phase 3 trial has the largest size.
Shape definition
▲ Up-triangle: study first submitted.
◼ Square: study completion(actual/anticipated).
⬤ Circle: result first posted.
Color definition
▶ Green: study is ongoing.
▶ Blue: recruitment completed.
▶ Red: study aborted/terminated/withdrawn.
▶ Pink: study in abnormal state.
US FDA submission
Size of symbol reflects the type of submission. E.g. Type 1 drug has the largest size.
◆: Approved.
◆: Tentative Approval.
Drug marketing & current status
Circle bubble denotes new drug marketing. Size is determined by drug type and market(i.e. population) size. E.g. Type 1 drug marketed in US has the largest size. Drug marketed in CA has the smallest size due to small population size.
Color definition
⬤ Blue circle: drug marketed (EU,CA), FDA submission approved (US).
⬤ Cyan circle: drug approved (CA), tentative approval (US), received positive opinion (EU)
⬤ Red circle: drug marketed/approved on the corresponding day but was later withdrawn, discontinued, cancelled, or received negative opinion.
Drug marketing status change
Square bubble denotes marketing status change. Size is determined by drug type and market(i.e. population) size.
Color definition
◼ Blue square: change from other status to marketed.
◼ Cyan square: change from other status to tentative status.
◼ Red square: change from other status to abnormal or withdrawn status.
Clinical Trials Summary Statistics
| Year | Recruiting | Enrolling By Invitation | Active, Not Recruiting | Not Yet Recruiting | Completed | Terminated | Withdrawn |
|---|---|---|---|---|---|---|---|
| ALL | 5 ⬤ | 7 ⬤ | 4 ⬤ | 133 ⬤ | 13 | 8 | |
| 2024 | 1 ⬤ | 3 ⬤ | 1 ⬤ | ||||
| 2023 | 4 ⬤ | 1 ⬤ | 4 ⬤ | ||||
| 2022 | 1 ⬤ | 4 ⬤ | 1 |
| Year | Recruiting | Enrolling By Invitation | Active, Not Recruiting | Not Yet Recruiting | Completed | Terminated | Withdrawn |
|---|---|---|---|---|---|---|---|
| ALL | 5 ⬤ | 7 ⬤ | 11 | 4 ⬤ | 1 | ||
| 2024 | |||||||
| 2023 | 1 ⬤ | ||||||
| 2022 | 1 ⬤ | 1 ⬤ |
| Year | Recruiting | Enrolling By Invitation | Active, Not Recruiting | Not Yet Recruiting | Completed | Terminated | Withdrawn |
|---|---|---|---|---|---|---|---|
| ALL | 9 ⬤ | 9 ⬤ | 95 ⬤ | 16 | 9 ⬤ | ||
| 2024 | 2 ⬤ | ||||||
| 2023 | 3 ⬤ | 1 | 1 | ||||
| 2022 | 1 ⬤ | 1 ⬤ | 1 ⬤ |
| Year | Recruiting | Enrolling By Invitation | Active, Not Recruiting | Not Yet Recruiting | Completed | Terminated | Withdrawn |
|---|---|---|---|---|---|---|---|
| ALL | 3 ⬤ | 13 | |||||
| 2024 | |||||||
| 2023 | 3 ⬤ | ||||||
| 2022 |
| Year | Recruiting | Enrolling By Invitation | Active, Not Recruiting | Not Yet Recruiting | Completed | Terminated | Withdrawn |
|---|---|---|---|---|---|---|---|
| ALL | 17 ⬤ | 1 ⬤ | 18 ⬤ | 4 ⬤ | 207 ⬤ | 33 | 5 |
| 2024 | 1 ⬤ | 1 ⬤ | |||||
| 2023 | 5 ⬤ | 1 ⬤ | 1 ⬤ | 2 ⬤ | |||
| 2022 | 3 ⬤ | 4 ⬤ | 1 | 2 |
| Year | Recruiting | Enrolling By Invitation | Active, Not Recruiting | Not Yet Recruiting | Completed | Terminated | Withdrawn |
|---|---|---|---|---|---|---|---|
| ALL | 4 ⬤ | 6 ⬤ | 2 ⬤ | 51 ⬤ | 2 | 6 | |
| 2024 | 1 ⬤ | ||||||
| 2023 | 1 ⬤ | 1 ⬤ | |||||
| 2022 | 2 ⬤ | 1 | 1 |
| Year | Recruiting | Enrolling By Invitation | Active, Not Recruiting | Not Yet Recruiting | Completed | Terminated | Withdrawn |
|---|---|---|---|---|---|---|---|
| ALL | 1 | 1 | |||||
| 2024 | |||||||
| 2023 | |||||||
| 2022 | 1 |
- Recruiting
- Enrolling By Invitation
- Active, Not Recruiting
- Not Yet Recruiting
- Completed
- Terminated
- Withdrawn
| Year | Phase 1 | Phase 1|Phase 2 | Phase 2 | Phase 2|Phase 3 | Phase 3 | Phase 4 | Others |
|---|---|---|---|---|---|---|---|
| ALL | 5 ⬤ | 5 ⬤ | 9 ⬤ | 3 ⬤ | 17 ⬤ | 4 ⬤ | 1 |
| 2024 | 1 ⬤ | 2 ⬤ | 1 ⬤ | ||||
| 2023 | 4 ⬤ | 1 ⬤ | 3 ⬤ | 3 ⬤ | 5 ⬤ | 1 ⬤ | |
| 2022 | 1 ⬤ | 1 ⬤ | 3 ⬤ | 2 ⬤ | 1 |
| Year | Phase 1 | Phase 1|Phase 2 | Phase 2 | Phase 2|Phase 3 | Phase 3 | Phase 4 | Others |
|---|---|---|---|---|---|---|---|
| ALL | 1 ⬤ | ||||||
| 2024 | |||||||
| 2023 | 1 ⬤ | ||||||
| 2022 |
| Year | Phase 1 | Phase 1|Phase 2 | Phase 2 | Phase 2|Phase 3 | Phase 3 | Phase 4 | Others |
|---|---|---|---|---|---|---|---|
| ALL | 7 ⬤ | 7 ⬤ | 9 ⬤ | 18 ⬤ | 6 ⬤ | ||
| 2024 | |||||||
| 2023 | 1 | 1 ⬤ | |||||
| 2022 | 1 ⬤ | 1 ⬤ | 1 ⬤ | 4 ⬤ | 1 |
| Year | Phase 1 | Phase 1|Phase 2 | Phase 2 | Phase 2|Phase 3 | Phase 3 | Phase 4 | Others |
|---|---|---|---|---|---|---|---|
| ALL | 4 ⬤ | 4 ⬤ | 2 ⬤ | ||||
| 2024 | 3 ⬤ | 1 ⬤ | 1 ⬤ | ||||
| 2023 | 1 ⬤ | 2 ⬤ | 1 ⬤ | ||||
| 2022 | 1 |
| Year | Phase 1 | Phase 1|Phase 2 | Phase 2 | Phase 2|Phase 3 | Phase 3 | Phase 4 | Others |
|---|---|---|---|---|---|---|---|
| ALL | 133 ⬤ | 11 | 95 ⬤ | 13 | 207 ⬤ | 51 ⬤ | 1 |
| 2024 | 1 ⬤ | ||||||
| 2023 | 4 ⬤ | 1 | |||||
| 2022 | 4 ⬤ | 2 |
| Year | Phase 1 | Phase 1|Phase 2 | Phase 2 | Phase 2|Phase 3 | Phase 3 | Phase 4 | Others |
|---|---|---|---|---|---|---|---|
| ALL | 13 | 4 ⬤ | 16 | 33 | 2 | ||
| 2024 | |||||||
| 2023 | |||||||
| 2022 |
| Year | Phase 1 | Phase 1|Phase 2 | Phase 2 | Phase 2|Phase 3 | Phase 3 | Phase 4 | Others |
|---|---|---|---|---|---|---|---|
| ALL | 8 | 1 | 9 ⬤ | 5 | 6 | ||
| 2024 | |||||||
| 2023 | |||||||
| 2022 | 1 | 1 ⬤ | 1 |
| Phase | Recruiting | Enrolling By Invitation | Active, Not Recruiting | Not Yet Recruiting | Completed | Terminated | Withdrawn |
|---|---|---|---|---|---|---|---|
| Phase 1 | 5 ⬤ | 7 ⬤ | 4 ⬤ | 133 ⬤ | 13 | 8 | |
| Phase 1|Phase 2 | 5 ⬤ | 7 ⬤ | 11 | 4 ⬤ | 1 | ||
| Phase 2 | 9 ⬤ | 9 ⬤ | 95 ⬤ | 16 | 9 ⬤ | ||
| Phase 2|Phase 3 | 3 ⬤ | 13 | |||||
| Phase 3 | 17 ⬤ | 1 ⬤ | 18 ⬤ | 4 ⬤ | 207 ⬤ | 33 | 5 |
| Phase 4 | 4 ⬤ | 6 ⬤ | 2 ⬤ | 51 ⬤ | 2 | 6 | |
| Others | 1 | 1 |
| Phase | Recruiting | Enrolling By Invitation | Active, Not Recruiting | Not Yet Recruiting | Completed | Terminated | Withdrawn |
|---|---|---|---|---|---|---|---|
| Phase 1 | 1 ⬤ | 3 ⬤ | 1 ⬤ | ||||
| Phase 1|Phase 2 | |||||||
| Phase 2 | 2 ⬤ | ||||||
| Phase 2|Phase 3 | |||||||
| Phase 3 | 1 ⬤ | 1 ⬤ | |||||
| Phase 4 | 1 ⬤ | ||||||
| Others |
| Phase | Recruiting | Enrolling By Invitation | Active, Not Recruiting | Not Yet Recruiting | Completed | Terminated | Withdrawn |
|---|---|---|---|---|---|---|---|
| Phase 1 | 4 ⬤ | 1 ⬤ | 4 ⬤ | ||||
| Phase 1|Phase 2 | 1 ⬤ | ||||||
| Phase 2 | 3 ⬤ | 1 | 1 | ||||
| Phase 2|Phase 3 | 3 ⬤ | ||||||
| Phase 3 | 5 ⬤ | 1 ⬤ | 1 ⬤ | 2 ⬤ | |||
| Phase 4 | 1 ⬤ | 1 ⬤ | |||||
| Others |
| Phase | Recruiting | Enrolling By Invitation | Active, Not Recruiting | Not Yet Recruiting | Completed | Terminated | Withdrawn |
|---|---|---|---|---|---|---|---|
| Phase 1 | 1 ⬤ | 4 ⬤ | 1 | ||||
| Phase 1|Phase 2 | 1 ⬤ | 1 ⬤ | |||||
| Phase 2 | 1 ⬤ | 1 ⬤ | 1 ⬤ | ||||
| Phase 2|Phase 3 | |||||||
| Phase 3 | 3 ⬤ | 4 ⬤ | 1 | 2 | |||
| Phase 4 | 2 ⬤ | 1 | 1 | ||||
| Others | 1 |
Note: "Year" represents clinical trail start year determined by study first submit date.
Three grouping strategies present the same statistical data from different angles, choose any one you are comfortable with.
⬤ at least one study with latest update posted within 7 days.
⬤ at least one study with latest update posted within 30 days.
⬤ at least one study with latest update posted within 90 days.
Clinical Trials Records
| Sponsor | Overall Status | Phase | Brief Title | Disease Condition | Intervention Name | Study First Submit Date | Last Update Post Date | Results First Post Date | Completion Date | Completion Date Type | Enrollment Count |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda | Recruiting | Phase 3 | A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis | Generalized Pustular Psoriasis|Erythrodermic Psoriasis | TAK-279 | 2024-03-15 | 2024-04-10 | 2026-03-27 | Anticipated | 20 | |
| Takeda | Not yet recruiting | Phase 3 | A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | Crohn's Disease | Vedolizumab|Upadacitinib|Placebo | 2024-01-19 | 2024-02-08 | 2028-08-01 | Anticipated | 396 | |
| Takeda | Recruiting | Phase 3 | Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) | Alpha1-Antitrypsin Deficiency | Fazirsiran Injection|Placebo | 2023-12-01 | 2024-04-25 | 2028-08-26 | Anticipated | 50 | |
| Takeda | Recruiting | Phase 3 | A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period | Plaque Psoriasis | TAK-279|Placebo|Apremilast | 2023-10-25 | 2024-04-09 | 2026-06-10 | Anticipated | 1000 | |
| Takeda | Not yet recruiting | Phase 3 | A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease | Ulcerative Colitis|Crohn's Disease | Vedolizumab IV|Vedolizumab SC | 2023-10-17 | 2024-04-12 | 2027-06-30 | Anticipated | 70 | |
| Takeda | Recruiting | Phase 3 | A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment | Plaque Psoriasis | TAK-279|Placebo|Apremilast | 2023-10-12 | 2024-04-09 | 2026-04-15 | Anticipated | 600 | |
| Takeda | Not yet recruiting | Phase 3 | A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases | Primary Immunodeficiency Diseases (PID) | TAK-881 | 2023-10-04 | 2023-10-11 | 2027-05-07 | Anticipated | 39 | |
| Takeda | Recruiting | Phase 3 | A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India | Healthy Volunteers | TDV|Placebo | 2023-09-22 | 2024-04-26 | 2025-04-01 | Anticipated | 480 | |
| Takeda | Recruiting | Phase 2|Phase 3 | Extension Study of Idursulfase-IT Along With Elaprase in Children and Adults With Hunter Syndrome and Cognitive Impairment | Hunter Syndrome | Idursulfase-IT|Elaprase | 2023-09-04 | 2024-04-04 | 2034-06-01 | Anticipated | 8 | |
| Takeda | Enrolling by invitation | Phase 3 | An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease | Alpha1-Antitrypsin Deficiency | Fazirsiran Injection | 2023-06-02 | 2024-03-15 | 2026-05-29 | Anticipated | 37 | |
| Takeda | Recruiting | Phase 3 | A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease | Crohn's Disease | Vedolizumab IV|Placebo | 2023-04-20 | 2023-09-29 | 2031-05-30 | Anticipated | 408 | |
| Takeda | Recruiting | Phase 2|Phase 3 | A Study of TAK-861 for the Treatment of Selected Central Hypersomnia Conditions | Narcolepsy Type 1|Narcolepsy Type 2 | TAK-861 | 2023-03-31 | 2024-02-16 | 2026-12-31 | Anticipated | 160 | |
| Takeda | Recruiting | Phase 2|Phase 3 | A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases | Primary Immunodeficiency Diseases (PID) | TAK-881|HYQVIA | 2023-01-26 | 2024-04-18 | 2026-09-30 | Anticipated | 75 | |
| Takeda | Active, not recruiting | Phase 3 | A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A | Hemophilia A | Adynovate | 2023-01-23 | 2024-04-05 | 2024-10-08 | Anticipated | 37 | |
| Takeda | Recruiting | Phase 3 | Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein | Alpha1-Antitrypsin Deficiency | Fazirsiran Injection|Placebo | 2022-12-28 | 2024-03-29 | 2029-03-31 | Anticipated | 160 | |
| Takeda | Not yet recruiting | Phase 3 | A Study of Recombinant Von Willebrand Factor (rVWF) (TAK-577) in Children With Severe Von Willebrand Disease (vWD) | Von Willebrand Disease (VWD) | Recombinant von Willebrand Factor (rVWF)|ADVATE | 2022-10-14 | 2023-06-02 | 2027-02-20 | Anticipated | 24 | |
| Takeda | Active, not recruiting | Phase 3 | A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS) | Alagille Syndrome (ALGS) | TAK-625 | 2022-09-14 | 2023-11-07 | 2025-07-24 | Anticipated | 7 | |
| Takeda | Active, not recruiting | Phase 3 | A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) | Progressive Familial Intrahepatic Cholestasis (PFIC) | TAK-625 | 2022-09-14 | 2023-11-07 | 2025-05-09 | Anticipated | 5 | |
| Takeda | Active, not recruiting | Phase 3 | A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease | Gaucher Disease | Velaglucerase Alfa | 2022-09-02 | 2024-02-22 | 2024-08-25 | Anticipated | 20 | |
| Takeda | Active, not recruiting | Phase 3 | A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants | Primary Immunodeficiency Diseases (PID) | TAK-771 | 2022-08-22 | 2024-02-20 | 2025-04-30 | Anticipated | 15 | |
| Takeda | Completed | Phase 3 | A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE) | Hereditary Angioedema (HAE) | Lanadelumab | 2022-07-13 | 2024-01-22 | 2023-11-28 | Actual | 20 | |
| Takeda | Recruiting | Phase 3 | A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD) | Ulcerative Colitis|Crohn's Disease | Vedolizumab IV|No Intervention | 2022-06-30 | 2024-03-06 | 2031-08-15 | Anticipated | 240 | |
| Takeda | Recruiting | Phase 3 | A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Children and Teenage Transplant Recipients With CMV Infection | Cytomegalovirus (CMV) | Maribavir | 2022-04-01 | 2024-04-08 | 2026-11-22 | Anticipated | 80 | |
| Takeda | Completed | Phase 3 | A Single Heterologous Booster Vaccination Study of TAK-019 in Healthy Japanese Adults (COVID-19) | Coronavirus Disease (COVID-19) | TAK-019 | 2022-03-27 | 2023-11-28 | 2023-07-28 | 2023-10-18 | Actual | 150 |
Note: Use 'Search' box on top right cornor to narrow down search results. E.g. type in "phase 3" (case insensitive, with double quote) to show Phase 3 trials.
⬤ latest update posted within 7 days.
⬤ latest update posted within 30 days.
⬤ latest update posted within 90 days.
US FDA Submission Summary Statistics*
| Year | TYPE 1 | TYPE 2 | TYPE 3 | TYPE 4 | TYPE 5 | TYPE 7 |
|---|---|---|---|---|---|---|
| ALL | 23 | 1 | 13 | 6 | 1 | 1 |
| 2024 | ||||||
| 2023 | 1 | 1 | ||||
| 2022 |
Note: "Year" determined by submission status date.
* Original submissions only. Supplementary records not counted.
⬤ at least one submission within 7 days.
⬤ at least one submission within 30 days.
⬤ at least one submission within 90 days.
US FDA Submission Records
| Sponsor | Application Type | Drug Name | Active Ingredient | Submission Code | Submission Type | Submission Status | Status Date | Application Number |
|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | BLA | Entyvio | Vedolizumab | Orig 1 | Approval | 2024-04-18 | 761359 | |
| Takeda Pharms Usa | NDA | Eohilia | Budesonide | Orig 1 | Approval | 2024-02-09 | 213976 | |
| Takeda Pharms Usa | NDA | Fruzaqla | Fruquintinib | Type 1 | Orig | Approval | 2023-11-08 | 217564 |
| Takeda Pharms Usa | BLA | Entyvio | Vedolizumab | Type 5 | Orig | Approval | 2023-09-27 | 761133 |
Note: Use 'Search' box on top right cornor to narrow down search results. E.g. type in "NDA" (case insensitive) to show records with "NDA" (New Drug Applications) tag.
⬤ submission status date within 7 days.
⬤ submission status date within 30 days.
⬤ submission status date within 90 days.
| Category | Sponsor | Marketing Date | Current Marketing Status | Drug Name | Active Ingredient | Submission Status Date | Submission Code | Submission Status | Marketing Status Change Date |
|---|---|---|---|---|---|---|---|---|---|
| Human Non-Bioproduct | Takeda Pharms Usa | 2023-11-08 | Prescription | Fruzaqla | Fruquintinib | 2023-11-08 | Type 1 | Approval | 2023-11-30 |
| Human Non-Bioproduct | Takeda Pharms Usa | 2023-11-08 | Prescription | Fruzaqla | Fruquintinib | 2023-11-08 | Type 1 | Approval | 2023-11-30 |
| Human Non-Bioproduct | Takeda Pharms Usa | 2023-09-27 | Prescription | Entyvio | Vedolizumab | 2023-09-27 | Type 5 | Approval | 2023-11-30 |
| Human Non-Bioproduct | Takeda Pharms Usa | 2023-09-27 | Prescription | Entyvio | Vedolizumab | 2023-09-27 | Type 5 | Approval | 2023-11-30 |
| Human Non-Bioproduct | Takeda Pharms Usa | 2013-01-25 | Discontinued | Oseni | Alogliptin Benzoate; Pioglitazone Hydrochloride | 2013-01-25 | Type 4 | Approval | 2022-03-29 |
| Human Non-Bioproduct | Takeda Pharms Usa | 2013-01-25 | Discontinued | Oseni | Alogliptin Benzoate; Pioglitazone Hydrochloride | 2013-01-25 | Type 4 | Approval | 2022-03-29 |
| Human Non-Bioproduct | Takeda Pharms Usa | 2005-08-29 | Discontinued | Actoplus Met | Metformin Hydrochloride; Pioglitazone Hydrochloride | 2005-08-29 | Type 4 | Approval | 2023-11-30 |
| Human Bioproduct | Takeda Pharmaceuticals U.S.A., Inc. | 2023-11-26 | Marketed | Adzynma | Adamts13, Recombinant Krhn | ||||
| Human Bioproduct | Takeda Pharmaceuticals U.S.A., Inc. | 2023-11-26 | Marketed | Adynovate | Antihemophilic Factor (Recombinant), Pe Gylated |
Note: This table contains human and animal drugs regulated by US FDA, and biological products regulated by CBER (Center for Biologics Evaluation and Research).
Use 'Search' box on top right cornor to narrow down search results. E.g. type in "discontinued" (case insensitive) to show discontinued drug products.
For human non-bioproduct, marketing date was set to submission approval date.
Possible marketing statuses: Marketed, Prescription, Over-the-counter, Discontinued, None (Tentative Approval).
⬤ any of (marketing/submission/status change) within 7 days.
⬤ any of (marketing/submission/status change) within 30 days.
⬤ any of (marketing/submission/status change) within 90 days.
| Category | Sponsor | Authorization Date | Current Marketing Status | Latest Status Update | Drug Name | Active Ingredient | Withdraw Date | Opinion Date | Summary of Opinion |
|---|---|---|---|---|---|---|---|---|---|
| Human | Takeda Gmb H | 2022-12-05 | Authorised | 2022-12-16 | Qdenga | Dengue Virus, Serotype 2, Expressing Dengue Virus, Serotype 1, Surface Proteins, Live, Attenuated, D | |||
| Human | Takeda Pharmaceuticals International Ag Ireland Branch | 2022-11-09 | Authorised | 2022-11-24 | Livtencity | Maribavir | |||
| Human | Takeda Gmb H | 2009-06-11 | Withdrawn | 2022-01-19 | Pantoloc Control | Pantoprazole | |||
| Human | Takeda Pharma A/S | 2007-12-11 | Withdrawn | 2022-10-18 | Glubrava | Metformin Hydrochloride, Pioglitazone Hydrochloride | |||
| Human | Takeda Pharma A/S | 2000-10-11 | Withdrawn | 2022-10-17 | Glustin | Pioglitazone Hydrochloride | |||
| Human | Takeda Pharma A/S | Withdrawn | Exkivity, | Mobocertinib | 2022-07-20 | ||||
| Human | Takeda Pharmaceuticals International Ag Ireland Branch | Summary of Opinion | Takhzyro, | Lanadelumab | 2023-09-14 | Positive | |||
| Human | Takeda Pharmaceuticals International Ag Ireland Branch | Summary of Opinion | Revestive, | Teduglutide | 2023-04-26 | Positive |
Note: This table contains human and animal drugs regulated by EMA (European Medicines Agency), and summary of opinion published by EMA based on the CHMP's or CVMP's positive or negative recommendation.
Use 'Search' box on top right cornor to narrow down search results. E.g. type in "withdrawn" (case insensitive) to show drugs withdrawn.
Possible marketing statuses: Authorised, Refused, Withdrawn, Summary of Opinion.
Summary of Opinion: published by European Medicines Agency (EMA) based on the CHMP's or CVMP's positive or negative recommendation. Further marketing authorization is partially based on this opinion.
⬤ any of (authorization/withdrawn/opinion/status change) date within 7 days.
⬤ any of (authorization/withdrawn/opinion/status change) date within 30 days.
⬤ any of (authorization/withdrawn/opinion/status change) date within 90 days.
| Category | Sponsor | Authorization Date | Current Marketing Status | Status Date | Drug Name | Active Ingredient |
|---|---|---|---|---|---|---|
| Human | Takeda Canada Inc | 1997-11-19 | Cancelled Post Market | 2024-02-19 | Agrylin | Anagrelide (Anagrelide Hydrochloride) (0.5 Mg) |
| Human | Takeda Canada Inc | 2021-11-12 | Marketed | 2024-01-02 | Glassia | Alpha1 Proteinase Inhibitor (Human) (1000 Mg) |
| Human | Takeda Canada Inc | 2022-01-14 | Marketed | 2023-11-07 | Hyqvia | Immunoglobulin (Human) (2.5 G)|Hyaluronidase (Human Recombinant) (200 Unit) |
| Human | Takeda Canada Inc | 2022-01-14 | Marketed | 2023-11-07 | Hyqvia | Immunoglobulin (Human) (5 G)|Hyaluronidase (Human Recombinant) (400 Unit) |
| Human | Takeda Canada Inc | 2022-01-14 | Marketed | 2023-11-07 | Hyqvia | Immunoglobulin (Human) (10 G)|Hyaluronidase (Human Recombinant) (800 Unit) |
| Human | Takeda Canada Inc | 2022-01-14 | Marketed | 2023-11-07 | Hyqvia | Immunoglobulin (Human) (20 G)|Hyaluronidase (Human Recombinant) (1600 Unit) |
| Human | Takeda Canada Inc | 2022-01-14 | Marketed | 2023-11-07 | Hyqvia | Immunoglobulin (Human) (30 G)|Hyaluronidase (Human Recombinant) (2400 Unit) |
| Human | Takeda Canada Inc | 2018-09-04 | Cancelled Pre Market | 2023-08-09 | Feiba Nf | Anti Inhibitor Coagulant Complex (650 Unit) |
| Human | Takeda Pharmaceuticals U.S.A., Inc. | 2015-02-11 | Marketed | 2023-06-29 | Iclusig | Ponatinib (Ponatinib Hydrochloride) (15 Mg) |
| Human | Takeda Canada Inc | 2006-10-17 | Cancelled Post Market | 2023-04-25 | Fosrenol | Lanthanum (Lanthanum Carbonate Hydrate) (250 Mg) |
| Human | Takeda Canada Inc | 2022-09-15 | Marketed | 2022-10-25 | Livtencity | Maribavir (200 Mg) |
| Human | Takeda Pharmaceuticals U.S.A., Inc. | 2015-02-11 | Dormant | 2022-08-08 | Iclusig | Ponatinib (Ponatinib Hydrochloride) (45 Mg) |
| Human | Takeda Canada Inc | 2020-09-25 | Marketed | 2022-02-28 | Takhzyro | Lanadelumab (300 Mg) |
| Human | Takeda Canada Inc | 1997-06-11 | Marketed | 2022-02-09 | Gammagard S/D | Immunoglobulin (Human) (5 G) |
| Human | Takeda Canada Inc | 1998-04-15 | Marketed | 2022-01-28 | Antithrombin Iii Nf | Antithrombin Iii (Human) (1100 Unit) |
| Human | Takeda Canada Inc | 2018-09-19 | Marketed | 2022-01-12 | Takhzyro | Lanadelumab (300 Mg) |
Note: This table contains human, animal drugs, radiopharmaceutical and disinfectant regulated by CFIA(Canadian Food Inspection Agency) and Health Canada.
Use 'Search' box on top right cornor to narrow down search results. E.g. type in "marketed" (case insensitive) to show drugs marketed.
Possible marketing statuses: Marketed, Approved, Dormant, Cancelled Pre Market, Cancelled Post Market, Cancelled (Safety Issue), Cancelled (Unreturned Annual).
⬤ any of (authorization/status change) date within 7 days.
⬤ any of (authorization/status change) date within 30 days.
⬤ any of (authorization/status change) date within 90 days.